Literature DB >> 28521607

Intravenous Fish Oil and Pediatric Intestinal Failure-Associated Liver Disease: Changes in Plasma Phytosterols, Cytokines, and Bile Acids and Erythrocyte Fatty Acids.

Kara L Calkins1, Andrea DeBarber2, Robert D Steiner2,3, Martiniano J Flores4, Tristan R Grogan5, Susanne M Henning6, Laurie Reyen7, Robert S Venick7.   

Abstract

BACKGROUND: Soybean oil (SO) emulsions are associated with intestinal failure-associated liver disease (IFALD); fish oil (FO) emulsions are used to treat IFALD. SO and FO differ with respect to their fatty acid and phytosterol content. In children with IFALD whose SO was replaced with FO, we aimed to (1) quantify changes in erythrocyte fatty acids and plasma phytosterols, cytokines, and bile acids and (2) correlate these changes with direct bilirubin (DB).
DESIGN: This study enrolled IFALD children who received 6 months of FO. Blood samples were collected prior to FO, and after 2 weeks and 3 and 6 months of FO. The primary outcome was 3-month vs baseline biomarker concentrations.
RESULTS: At study initiation, the median patient age was 3 months (interquartile range, 3-17 months), and mean ± standard deviation DB was 5.6 ± 0.7 mg/dL (n = 14). Cholestasis reversed in 79% of subjects. Eicosapentaenoic and docosahexaenoic acid was greater than baseline (P < .001, all time points). Linoleic and arachidonic acid and sitosterol and stigmasterol were less than baseline (P < .05, all time points). Three- and 6-month interleukin-8 (IL-8) and total and conjugated bile acids were less than baseline (P < .05). Baseline IL-8 was correlated with baseline DB (r = 0.71, P < .01). Early changes in stigmasterol and IL-8 were correlated with later DB changes (r = 0.68 and 0.75, P < .05).
CONCLUSION: Specific fat emulsion components may play a role in IFALD. Stigmasterol and IL-8 may predict FO treatment response.
© 2017 American Society for Parenteral and Enteral Nutrition.

Entities:  

Keywords:  cytokines; fatty acids; life cycle; lipids; liver disease; nutrition; parenteral nutrition; pediatrics; short bowel syndrome

Mesh:

Substances:

Year:  2017        PMID: 28521607      PMCID: PMC5665720          DOI: 10.1177/0148607117709196

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   3.896


  24 in total

1.  Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury.

Authors:  Karim C El Kasmi; Aimee L Anderson; Michael W Devereaux; Sophie A Fillon; J Kirk Harris; Mark A Lovell; Milton J Finegold; Ronald J Sokol
Journal:  Hepatology       Date:  2012-03-18       Impact factor: 17.425

2.  Parenteral plant sterols and intestinal failure-associated liver disease in neonates.

Authors:  Annika Kurvinen; Markku J Nissinen; Sture Andersson; Päivi Korhonen; Tarja Ruuska; Mari Taimisto; Marko Kalliomäki; Liisa Lehtonen; Ulla Sankilampi; Pekka Arikoski; Timo Saarela; Tatu A Miettinen; Helena Gylling; Mikko P Pakarinen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-06       Impact factor: 2.839

3.  Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children.

Authors:  Hau D Le; Vincent E de Meijer; Elizabeth M Robinson; David Zurakowski; Alexis K Potemkin; Danielle A Arsenault; Erica M Fallon; Alpin Malkan; Bruce R Bistrian; Kathleen M Gura; Mark Puder
Journal:  Am J Clin Nutr       Date:  2011-07-20       Impact factor: 7.045

4.  Association of serum interleukin-8 levels with the degree of fibrosis in infants with chronic liver disease.

Authors:  Valerio Nobili; Matilde Marcellini; Luigi Giovannelli; Elia Girolami; Flaminia Muratori; Germana Giannone; Rita Devito; Fabrizio De Benedetti
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-11       Impact factor: 2.839

5.  Sterol profiling in red blood cell membranes and plasma of newborns receiving total parenteral nutrition.

Authors:  P Pianese; G Salvia; A Campanozzi; O D'Apolito; A Dello Russo; M Pettoello-Mantovani; G Corso
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

6.  Serum plant sterols, cholestanol, and cholesterol precursors associate with histological liver injury in pediatric onset intestinal failure.

Authors:  Annika Mutanen; Markku J Nissinen; Jouko Lohi; Päivi Heikkilä; Helena Gylling; Mikko P Pakarinen
Journal:  Am J Clin Nutr       Date:  2014-08-06       Impact factor: 7.045

7.  Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats.

Authors:  Nerea Pérez-Echarri; Patricia Pérez-Matute; Beatriz Marcos-Gómez; Amelia Marti; J Alfredo Martínez; María J Moreno-Aliaga
Journal:  J Nutr Biochem       Date:  2008-09-30       Impact factor: 6.048

Review 8.  Phytosterols in human nutrition.

Authors:  Richard E Ostlund
Journal:  Annu Rev Nutr       Date:  2002-04-04       Impact factor: 11.848

9.  First year growth of preterm infants fed standard compared to marine oil n-3 supplemented formula.

Authors:  S E Carlson; R J Cooke; S H Werkman; E A Tolley
Journal:  Lipids       Date:  1992-11       Impact factor: 1.880

10.  Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis.

Authors:  Henning W Zimmermann; Sebastian Seidler; Nikolaus Gassler; Jacob Nattermann; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

View more
  8 in total

1.  MicroRNA 122 Reflects Liver Injury in Children with Intestinal Failure-Associated Liver Disease Treated with Intravenous Fish Oil.

Authors:  Kara L Calkins; Shanthie Thamotharan; Shubamoy Ghosh; Yun Dai; Sherin U Devaskar
Journal:  J Nutr       Date:  2020-05-01       Impact factor: 4.798

Review 2.  Progress and perspectives in plant sterol and plant stanol research.

Authors:  Peter J H Jones; Maryam Shamloo; Dylan S MacKay; Todd C Rideout; Semone B Myrie; Jogchum Plat; Jean-Baptiste Roullet; David J Baer; Kara L Calkins; Harry R Davis; P Barton Duell; Henry Ginsberg; Helena Gylling; David Jenkins; Dieter Lütjohann; Mohammad Moghadasian; Robert A Moreau; David Mymin; Richard E Ostlund; Rouyanne T Ras; Javier Ochoa Reparaz; Elke A Trautwein; Stephen Turley; Tim Vanmierlo; Oliver Weingärtner
Journal:  Nutr Rev       Date:  2018-10-01       Impact factor: 7.110

3.  Intestinal Failure-Associated Liver Disease and Eicosapentaenoic Acid/Arachidonic Acid Ratio.

Authors:  Wataru Miura; Nobuhiko Nagano; Ryota Kato; Aya Okahashi; Kayo Yoshikawa; Kensuke Ohashi; Tsugumichi Koshinaga; Ichiro Morioka
Journal:  Indian J Pediatr       Date:  2019-02-13       Impact factor: 1.967

Review 4.  Altered nutrient status reprograms host inflammation and metabolic health via gut microbiota.

Authors:  Rachel M Golonka; Xia Xiao; Ahmed A Abokor; Bina Joe; Matam Vijay-Kumar
Journal:  J Nutr Biochem       Date:  2020-02-22       Impact factor: 6.048

5.  Intravenous Fish Oil and Serum Fatty Acid Profiles in Pediatric Patients With Intestinal Failure-Associated Liver Disease.

Authors:  Margaret L Ong; Robert S Venick; Stephen B Shew; James C Y Dunn; Laurie Reyen; Tristan Grogan; Kara L Calkins
Journal:  JPEN J Parenter Enteral Nutr       Date:  2019-03-22       Impact factor: 4.016

6.  Pregnancy and weaning regulate human maternal liver size and function.

Authors:  Alexandra Q Bartlett; Kimberly K Vesco; Jonathan Q Purnell; Melanie Francisco; Erica Goddard; Xiangnan Guan; Andrea DeBarber; Michael C Leo; Eric Baetscher; William Rooney; Willscott Naugler; Alexander R Guimaraes; Patrick Catalano; Zheng Xia; Pepper Schedin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-30       Impact factor: 11.205

Review 7.  IFALD in children: What's new? A narrative review.

Authors:  Fabiola Di Dato; Raffaele Iorio; Maria Immacolata Spagnuolo
Journal:  Front Nutr       Date:  2022-07-25

Review 8.  Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure.

Authors:  Fedja A Rochling
Journal:  Nutrients       Date:  2021-03-10       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.